Shares of GW Pharmaceuticals PLC-ADR GWPH 1.12% are up nearly 120 percent in early Monday trading after the company announced positive Phase III data on Epidiolex. The study found that the drug significantly reduced seizures in children suffering from Dravet Syndrome, a condition for which there are currently no FDA-approved treatments.

“The results of this Epidiolex pivotal trial are important and exciting as they represent the first placebo-controlled evidence to support the safety and efficacy of pharmaceutical cannabidiol in children with Dravet Syndrome, one of the most severe and difficult-to-treat types of epilepsy,” Dr. Orrin Devinsky said in the company’s press release.

“The data suggests that they could file on the basis of this study rather than wait for the next three, which, if they do, could drive the price even higher,” Alan Brochstein, author of 420 Investor, told Benzinga.

Most marijuana stocks were…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!